Reported or emerging application areas include joint disorders [33, 34], psychotic and neurocognitive conditions [35], cardiovascular disease [36], and gastrointestinal disorders [37,38,39]

DOI: Published online: August 18, 2021 1 Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, College of Medicine, Rochester, MN, USA 2 Department of Neurology, Mayo Clinic, College of Medicine, Rochester, MN, USA 3 Department of Psychiatry and Psychology, Mayo Clinic, College of Medicine, Rochester, MN, USA 4 Department of Neuroscience Program, Mayo Clinic, College of Medicine, Rochester, MN, USA Corresponding author: Doo-Sup Choi, PhD Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, College of Medicine, Rochester, 200 1st SW, MN 55905, USA / Tel: +1-507-284-5602 / Fax: +1-507-266-0824 / E-mail: [email protected] Copyright 2021 The Korean Movement Disorder Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited

Half-life ~10 minutes in plasma
For patients in Miami who are exploring options beyond GLP-1 medications, this mechanism is clinically meaningful
doi: 10.1111/j.1476-5381.1993.tb13429.x, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar] 79.Van der Kuy P, Merkus F, Russel F, Lohman J, Hooymans P
Weight regain: Without the appetite suppression and slowed digestion provided by the medication, weight lost during treatment may gradually return